文献速递炎症性肠病

IBD治疗不增加SARS-CoV-2感染不良结局风险:IG-IBD研究

Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-10-25

该观察性队列研究纳入937例炎症性肠病(IBD)患者,评估COVID-19不良结局的危险因素并构建风险指数。结果显示IBD药物未与不良结局相关,抗TNF药物在溃疡性结肠炎中与较低肺炎风险相关、在克罗恩病中与较低住院和重症风险相关。

要点

  • 活动性疾病和合并症是IBD患者COVID-19不良结局的主要风险因素。
  • 未发现任何IBD药物与COVID-19不良结局相关。
  • 抗TNF药物在UC中与较低肺炎风险相关,在CD中与较低住院和重症风险相关。

核心结论

  • IBD患者COVID-19病程与普通人群相似,IBD药物不增加不良结局风险,活动性疾病和合并症患者风险更高。

研究设计与样本

  • 观察性队列研究,纳入937例IBD患者(其中446例为溃疡性结肠炎),采用单变量和多变量逻辑回归分析危险因素。

主要发现

  • 128例(13.7%)为无症状SARS-CoV-2感染,664例(70.8%)病程良好,135例(15.5%)为中度或重度COVID-19。
  • UC患者中肥胖、活动性疾病和合并症与不良结局显著相关。
  • CD患者中年龄、肥胖、合并症和额外的免疫介导炎症性疾病为风险因素。
  • 多变量分析未发现任何IBD药物与不良COVID-19结局相关。
  • 抗TNF药物在UC中与较低肺炎风险相关,在CD中与较低住院和重症COVID-19风险相关。

关键数值与推荐

  • 研究将识别的风险因素纳入两个指数,用于识别UC或CD患者中COVID-19不良结局风险较高者。
  • 风险指数可能有助于识别应优先进行COVID-19再接种或SARS-CoV-2感染治疗的患者。

临床怎么用

  • IBD患者不应因担心COVID-19不良结局而停用IBD药物。
  • 对活动性疾病和合并症患者应加强监测,并可利用风险指数识别需优先再接种或治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older age and comorbidities are the main risk factors for adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. AIMS: To assess risk factors for adverse outcomes of COVID-19 in IBD patients and use the identified risk factors to build risk indices. METHODS: Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. RESULTS: Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS-CoV-2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID-19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune-mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID-19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID-19 outcomes, but anti-TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID-19 in CD. CONCLUSION: The course of COVID-19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID-19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID-19 re-vaccination or for therapies for SARS-CoV-2 infection.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bezzio C, Armuzzi A, Furfaro F, et al. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther. 2021. PMID: 34694009. doi:10.1111/apt.16663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。